Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)

NCT04233216 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1 Infection

Interventions

DRUG: ISL
DRUG: DOR
DRUG: DOR/ISL
DRUG: Placebo to ISL
DRUG: Placebo to DOR

Sponsor

Merck Sharp & Dohme LLC